Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

TAS-102 & Gastric cancer / Gastric adenocarcinoma / Stomach cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Approval status

TAS-102 (trifluridine/tipiracil; Lonsurf TM) is approved by both the FDA and EMA for adult patients with metastatic gastric cancer, including gastric/gastroesophageal junction adenocarcinoma, in adults who have undergone at least two prior lines of chemotherapy. These treatments must have included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and, if suitable, HER2-targeted therapy (3)

Clinical data

A phase III trial (TAGS) showed significant improvement in overall survi…

References (Sources)

Trifluridine/tipiracil in the treatment of gastric cancer
Fostea & Arkenau 2022 Future Oncol. 18(12): 1511-1517
Review
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Shitara et al. 2018a Lancet Oncology 19: 1437-1448
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers
Peeters et al. 2018
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!